The Latest Breaking News from Charles River Laboratories

Charles River Laboratories has continued to underperform the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Charles River Laboratories has significantly underperformed the Nasdaq Composite over the past year, yet analysts remain cautiously optimistic about the stock’s prospects.

Amid market turbulence and policy shifts, do two of the S&P 500’s steepest decliners, DECK and CRL, offer deep value or signal deeper trouble ahead?

Charles River Laboratories has lagged behind the broader market over the past year, with Wall Street analysts maintaining a cautious outlook on its future performance.

Charles River Laboratories is expected to announce its third-quarter results next month, and analysts predict a double-digit decline in the company’s bottom-line figure.

Charles River Laboratories underperformed the Dow recently, but Wall Street analysts remain moderately optimistic about the stock’s prospects.

Charles River Laboratories is poised to release its second-quarter earnings next month, and analysts expect a double-digit earnings dip.

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.17%. Stocks on Tuesday settled mixed. Reduced expectations for...

Horseshoe crab blood is used to test vaccines around the world. But while Europe has approved a synthetic alternative, biomedical labs are bleeding more crabs from the Atlantic Coast.